» Articles » PMID: 36221793

Stabilization of Estrogen Receptor α by USP37 Contributes to the Progression of Breast Cancer

Overview
Journal Cancer Sci
Specialty Oncology
Date 2022 Oct 12
PMID 36221793
Authors
Affiliations
Soon will be listed here.
Abstract

Breast cancer is a major cause of cancer-related morbidity and mortality in women. Estrogen receptor-positive breast cancer accounts for roughly 70%-80% of breast tumors, and estrogen receptor alpha (ERα) has been considered as a key driver in promoting breast cancer progression. In the present study, we identified USP37 as a novel modulator in modulating ERα ubiquitination and stability. The expression of USP37 was upregulated in ERα-positive breast cancer and correlated with ERα protein level. High expression of USP37 was associated with unfavorable prognosis. USP37 depletion resulted in significantly decreased ERα protein level, ERα target genes expression as well as the estrogen response element activity in breast cancer cells. Further mechanistic study revealed the interaction between USP37 and ERα: USP37 regulated ERα signaling through modulating protein stability instead of gene expression, in which it stabilized ERα protein via inhibiting the K48-specific polyubiquitination process. Additionally, USP37 depletion led to growth inhibition and cell cycle arrest of ERα-positive breast cancer cells, which could be further rescued by ERα overexpression. Overall, our study proposed a novel post-translational mechanism of ERα in promoting breast cancer progression. Targeting USP37 may be proved to be a promising strategy for patients with ERα-positive breast cancer.

Citing Articles

USP37 prevents premature disassembly of stressed replisomes by TRAIP.

Kochenova O, DAlessandro G, Pilger D, Schmid E, Richards S, Garcia M bioRxiv. 2024; .

PMID: 39282314 PMC: 11398331. DOI: 10.1101/2024.09.03.611025.


USP36 promotes tumorigenesis and tamoxifen resistance in breast cancer by deubiquitinating and stabilizing ERα.

Zhuang T, Zhang S, Liu D, Li Z, Li X, Li J J Exp Clin Cancer Res. 2024; 43(1):249.

PMID: 39215346 PMC: 11365244. DOI: 10.1186/s13046-024-03160-2.


Stabilization of estrogen receptor α by USP37 contributes to the progression of breast cancer.

Cao J, Wang X, Wang S, Chen Z, Tang J Cancer Sci. 2022; 114(5):2041-2052.

PMID: 36221793 PMC: 10154820. DOI: 10.1111/cas.15613.

References
1.
Tang J, Wu Z, Tian Z, Chen W, Wu G . OTUD7B stabilizes estrogen receptor α and promotes breast cancer cell proliferation. Cell Death Dis. 2021; 12(6):534. PMC: 8149656. DOI: 10.1038/s41419-021-03785-7. View

2.
Traboulsi T, El Ezzy M, Dumeaux V, Audemard E, Mader S . Role of SUMOylation in differential ERα transcriptional repression by tamoxifen and fulvestrant in breast cancer cells. Oncogene. 2018; 38(7):1019-1037. PMC: 6514857. DOI: 10.1038/s41388-018-0468-9. View

3.
Wang S, Luo H, Wang C, Sun H, Sun G, Sun N . RNF8 identified as a co-activator of estrogen receptor α promotes cell growth in breast cancer. Biochim Biophys Acta Mol Basis Dis. 2017; 1863(6):1615-1628. DOI: 10.1016/j.bbadis.2017.02.011. View

4.
Bhatt S, Xiao Z, Meng Z, Katzenellenbogen B . Phosphorylation by p38 mitogen-activated protein kinase promotes estrogen receptor α turnover and functional activity via the SCF(Skp2) proteasomal complex. Mol Cell Biol. 2012; 32(10):1928-43. PMC: 3347406. DOI: 10.1128/MCB.06561-11. View

5.
Flores J, Salcedo A, Fernandez L . Micellar electrokinetic chromatographic study of the separation of an aromatase inhibitor and a tryciclic antidepressant in the breast cancer treatment. Anal Chem Insights. 2009; 3:91-101. PMC: 2701177. DOI: 10.4137/aci.s939. View